Glenmark Pharmaceuticals gains as its US arm launches Phytonadione Injectable Emulsion
Glenmark Pharmaceuticals is currently trading at Rs. 1526.65, up by 22.40 points or 1.49% from its previous closing of Rs. 1504.25 on the BSE.
The scrip opened at Rs. 1505.05 and has touched a high and low of Rs. 1537.90 and Rs. 1505.05 respectively. So far 2341 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1830.05 on 15-Oct-2024 and a 52 week low of Rs. 766.65 on 15-Feb-2024.
Last one week high and low of the scrip stood at Rs. 1537.90 and Rs. 1440.05 respectively. The current market cap of the company is Rs. 43005.47 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 36.30% and 17.06% respectively.
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has launched Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. Glenmark’s Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.
According to IQVIATM, sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
